Enforcement shield ends for pharmacies compounding tirzepatide copies
State-licensed pharmacies can no longer compound copies of tirzepatide without falling outside FDA's no-action period, which may affect where patients get the drug and what they pay.
State-licensed pharmacies that compound copies of tirzepatide, the active ingredient in Mounjaro and Zepbound, lost their protection from FDA enforcement on February 18, 2025, when a 60-day wind-down period ended [1][2]. From this date, a 503A pharmacy compounding an "essentially a copy" of the commercially available brand product is no longer shielded by the drug's place on the national shortage list [1].
The clock started on December 19, 2024, when the FDA again determined that the tirzepatide shortage was resolved. The agency said supply "meets or exceeds current demand" and will also meet or exceed projected demand [1]. That decision followed a court-ordered re-evaluation of an earlier determination, and the FDA said it would continue monitoring the market and did not rule out adding tirzepatide back to the shortage list if warranted [1].
On February 11, 2025, the FDA said its position had not changed. The period during which it does not intend to take action against compounders for violations tied to tirzepatide's shortage listing runs for 503A pharmacies until February 18, 2025, or until a district court rules on a preliminary injunction motion in Outsourcing Facilities Association v. FDA, whichever is longer [2]. Outsourcing facilities operating under section 503B have a longer window, until March 19, 2025 [1][2].
What counts as "essentially a copy" is defined in FDA guidance. The agency intends to treat a compounded product that way when it contains the same active ingredient as an approved product in the same, similar or easily substitutable strength, and can be given by the same route of administration — unless a prescriber determines and documents that the compounded product contains a change producing a significant difference for an identified individual patient [2]. Under a narrow set of circumstances, such as documentation of medical necessity, 503A pharmacies may still compound tirzepatide, but they are prohibited from compounding essentially a copy of the commercial product [1].
Outsourcing facilities face a separate restriction. They may not compound from bulk drug substances unless the substance appears on the 503B bulks list or the compounded drug is on the FDA shortage list at the time of compounding, distribution and dispensing. Tirzepatide currently appears on neither list [2].
The no-action periods do not cover other requirements. The FDA said it may still act on violations of other statutory or regulatory rules, including findings that a product may be substandard quality or otherwise unsafe [1][2].
Why it matters for patients
Patients who received compounded tirzepatide from a 503A pharmacy may find that their pharmacy stops supplying that version of the drug. The FDA-approved tirzepatide products are Mounjaro and Zepbound [2]. Patients whose pharmacy can no longer make a copy may need to move to an approved product or to another option a prescriber and pharmacy can legally provide, and insurance coverage and out-of-pocket costs for those paths can differ. How many patients are affected and what they will pay have not been disclosed in these materials.
Compounding for an individual patient can continue in some cases. The FDA says a 503A pharmacy may still compound when a prescriber documents a clinical need, and the agency's copy definition allows for a documented significant difference for an identified patient [1][2]. The FDA has not said how it will weigh those individual determinations going forward.
What happens next
March 19, 2025 is the last day of the FDA's enforcement discretion window for 503B outsourcing facilities compounding tirzepatide copies [1][2]. The 503B lawsuit that produced the court-ordered re-evaluation of the shortage decision is still ongoing, and pharmacies have continued to report shortages, so the dates could shift [1].
The FDA's February 11, 2025 update ties the 503A window to the district court's decision on the preliminary injunction motion, whichever comes later [2]. The FDA has said it will keep monitoring supply and could restore tirzepatide to the shortage list [1]. For other GLP-1 drugs, dulaglutide, semaglutide injection and liraglutide injection were still listed as in shortage as of the FDA's December 2024 update [1][2].
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.